Compass Pathways Price Target Adjusted by H.C. Wainwright Following Anorexia Nervosa Program Update

Market Adjustment Following Anorexia Nervosa Program Update

H.C. Wainwright has adjusted its price target for Compass Pathways (CMPS) shares to $40 from $45, while retaining a "Buy" rating. This revision comes as Compass Pathways announced it would not proceed with further development of its anorexia nervosa program following the completion of a Phase 2 clinical trial. The market's reaction is leaning towards an uncertain to slightly bearish sentiment, as investors assess the implications of this strategic shift on the company's long-term growth trajectory.

Analyst's Rationale and Valuation Revision

The primary driver behind H.C. Wainwright's revised price target is the removal of the anorexia nervosa indication from its financial model. According to the analyst, this decision was made after Compass Pathways' Q2 report, which confirmed the cessation of the program. The discontinuation of the anorexia nervosa initiative is anticipated to lead to updated financial models and investor expectations for Compass Pathways, potentially affecting its future valuation and projected growth.

Clinical Trial Details and Strategic Reassessment

The Phase 2 clinical trial for anorexia nervosa investigated the safety and efficacy of COMP360 psilocybin treatment. This small, double-blind, randomized, and controlled multicenter study enrolled 32 participants. While the trial observed an encouraging positive signal, specifically a reduction in eating disorder and depressive symptoms in the 25-milligram arm sustained through 12 weeks, its statistical power was limited. This limitation was primarily due to the low overall participant count and a high number of dropouts within the control arm. Despite these statistical challenges, the study demonstrated a safe profile, consistent with the high-risk patient population in anorexia, with no unexpected safety signals reported. The company maintains that the findings support further exploration of COMP360 in anorexia nervosa. However, Compass Pathways is now strategically prioritizing its Treatment-Resistant Depression (TRD) trials, with an intensified focus on commercialization efforts for its lead candidate, COMP360, following successful Phase 3 trial results. The company is also actively pursuing clinical program design for Post-Traumatic Stress Disorder (PTSD).

Broader Research & Development Landscape

Compass Pathways' research and development strategy is now heavily concentrated on its TRD programs. The second pivotal Phase 3 trial for TRD (COMP006) is ongoing, with 26-week data expected in the second half of 2026. This focus is a result of a strategic reorganization in late 2024, which included decreased staffing levels and the discontinuation of certain early-stage research programs, thereby redirecting resources towards the late-stage development of COMP360. The company aims to accelerate patient access and explore pathways for a potential accelerated COMP360 filing for TRD, leveraging its Breakthrough Therapy designation.

Financial Position and Future Outlook

As of June 30, 2025, Compass Pathways reported cash and cash equivalents totaling $221.9 million, which are projected to fund operations into 2027. Research and development expenses for the second quarter of 2025 rose to $30.3 million, an increase from $29.1 million in the same period of 2024. This rise is mainly attributed to the advancement of the late-stage COMP360 Phase 3 clinical trials. The net loss for the second quarter of 2025 stood at $38.4 million, or $0.41 net loss per share. For the full year 2025, net cash used in operating activities is projected to range between $120 million and $145 million. While investor sentiment is cautiously optimistic due to clinical successes, uncertainties persist regarding the precise regulatory timeline, commercial launch, and long-term real-world durability of the treatment. The company is positioned to be the first listed psychedelics stock to submit an FDA new drug application, a significant milestone for the broader psychedelic-assisted therapy ecosystem. Despite a prior sell-off of approximately 52% following initial Phase 3 TRD data, reaching a low of $2.25 per share, the stock recovered to $4.34 per share by August 1, 2025, highlighting its speculative nature and market volatility.